Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Pulmonary dry powder vaccine of pneumococcal antigen loaded nanoparticles

Full text
Kunda, Nitesh K. [1, 2] ; Alfagih, Iman M. [1, 3] ; Miyaji, Eliane N. [4] ; Figueiredo, Douglas B. [4] ; Goncalves, Viviane M. [4] ; Ferreira, Daniela M. [5] ; Dennison, Sarah R. [6] ; Somavarapu, Satyanarayana [7] ; Hutcheon, Gillian A. [1] ; Saleem, Imran Y. [1]
Total Authors: 10
[1] Liverpool John Moores Univ, Formulat & Drug Delivery Res, Sch Pharm & Biomol Sci, Liverpool L3 3AF, Merseyside - England
[2] Univ New Mexico, Coll Pharm, Dept Pharmaceut Sci, Albuquerque, NM 87131 - USA
[3] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh - Saudi Arabia
[4] Inst Butantan, Ctr Biotecnol, Sao Paulo, SP - Brazil
[5] Univ Liverpool, Liverpool Sch Trop Med, Resp Infect Grp, Liverpool L3 5QA, Merseyside - England
[6] Univ Cent Lancashire, UCLan Biomed Res Facil Res & Innovat, Preston PR1 2HE, Lancs - England
[7] UCL, Sch Pharm, Dept Pharmaceut, London - England
Total Affiliations: 7
Document type: Journal article
Source: International Journal of Pharmaceutics; v. 495, n. 2, p. 903-912, NOV 30 2015.
Web of Science Citations: 14

Pneumonia, caused by Streptococcus pneumoniae, mainly affects the immunocompromised, the very young and the old, and remains one of the leading causes of death. A steady rise in disease numbers from non-vaccine serotypes necessitates a new vaccine formulation that ideally has better antigen stability and integrity, does not require cold-chain and can be delivered non-invasively. In this study, a dry powder vaccine containing an important antigen of S. pneumoniae, pneumococcal surface protein A (PspA) that has shown cross-reactivity amongst serotypes to be delivered via the pulmonary route has been formulated. The formulation contains the antigen PspA adsorbed onto the surface of polymeric nanoparticles encapsulated in L-leucine microparticles that can be loaded into capsules and delivered via an inhaler. We have successfully synthesized particles of similar to 150 nm and achieved similar to 20 mu g of PspA adsorption per mg of NPs. In addition, the spray-dried powders displayed a FPF of 74.31 +/- 1.32% and MMAD of 1.70 +/- 0.03 mu m suggesting a broncho-alveolar lung deposition facilitating the uptake of the nanoparticles by dendritic cells. Also, the PspA released from the dry powders maintained antigen stability (SDS-PAGE), integrity (Circular dichroism) and activity (lactoferrin binding assay). Moreover, the released antigen also maintained its antigenicity as determined by ELISA. (C) 2015 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 15/06255-6 - Development and production of new pneumococcal vaccines based on recombinant proteins
Grantee:Viviane Maimoni Gonçalves
Support type: Regular Research Grants
FAPESP's process: 12/04858-7 - Development of the purification process of the pneumococcal surface protein a from Clade4 (PspA4pro)
Grantee:Douglas Borges de Figueiredo
Support type: Scholarships in Brazil - Master